Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (322)	12/5/1998 5:05:00 PM
From: Rande Is	Read Replies (1) \| Respond to of 57584

BIPL: Biopool International Expands Distribution to National Accounts BusinessWire, Thursday, December 03, 1998 at 12:10 VENTURA, Calif.--(BUSINESS WIRE)--Dec. 3, 1998--Biopool International Inc. (NASDAQ:BIPL) Thursday announced that it has expanded its distribution agreement with Allegiance Healthcare Corp. in an effort to increase exposure to national purchasing groups. Biopool's immunohematology products (BCA product line) will be included in the Allegiance clinical laboratory products catalog and have recently been added to the national contract between Allegiance and Novation (formerly VHA), a national group purchasing organization that handles purchasing for more than 1,400 health care facilities in the United States. Allegiance is the sole hospital and laboratory product distributor contracted to supply Novation member facilities. Allegiance Healthcare, based in McGaw Park, Ill., is the principal U.S. subsidiary of Allegiance Corp. (NYSE:AEH). Through its subsidiaries, Allegiance is the leading provider of health-care products and cost-management services to hospitals, laboratories and other health care facilities. Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, commented: "In today's health care market, fewer than 10 national group purchasing organizations, or GPOs, control or influence the purchasing decisions, through national contracts, for some 90% of our target hospital accounts. Allegiance is a sole or primary contract vendor to nearly all of these national purchasing organizations and hospital corporations, such as Novation, Tenet and Premier. Recognizing the importance of presenting our company and products to these key decision makers, Biopool has created the new position of National Accounts Manager to work directly with Allegiance and the national contracting organizations. "The agreement has been expanded to include our 'flagship' red cell products, and we expect a significantly improved response from customers," continued Bick. "This 'open door' to important national contracting and purchasing organizations is a critical step in Biopool's overall growth strategy and is expected to enhance the company's ability to serve a much larger segment of the health care industry with Biopool's high-quality in vitro diagnostic reagents for hemostasis, blood group serology, and drugs of abuse testing." Founded in 1987, Biopool International develops, manufactures, and markets a full range of test kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function and the vascular system; specialty chemistry controls used to monitor and measure the presence of drugs of abuse; and blood group serology products used to screen for antibodies and group and type whole blood. The company's product line of more than 150 FDA-approved products is sold to hospitals, blood bank facilities, and clinical and reference laboratories on a worldwide basis by the company's own sales representatives, as well as through an extensive network of distributors. To learn more about Biopool, visit the company's Web site at biopool.com. NOTE: This news release contains forward-looking statements regarding the impact of an expanded distribution agreement which are based upon current expectations that involve a number of risks and uncertainties including, but not limited to, technological innovations of competitors, changes in health care regulations, litigation claims, foreign currency fluctuation, product acceptance or changes in government regulation of the company's products, as well as other factors discussed in the company's last Report on Form 10-K-SB under "Risk Factors." CONTACT: Biopool International Inc., Ventura Michael D. Bick and Carol Hill, 805/654-0643 KEYWORD: CALIFORNIA ILLINOIS INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICINE PHARMACEUTICAL Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1998, Business Wire